Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16416468 | 1.00 | MAPK1 (0.52) | MAPK1HPGDTSHRGSK3BF10 | |
| SCHEMBL1136065 | 0.88 | MAPK1 (0.52) | MAPK1HPGDTSHRGSK3BF10 | |
| SCHEMBL1136066 | 0.88 | MAPK1 (0.52) | MAPK1HPGDTSHRGSK3BF10 | |
| SCHEMBL15221118 | 0.88 | MAPK1 (0.52) | MAPK1HPGDTSHRGSK3BF10 | |
| SCHEMBL14838637 | 0.86 | MAPK1 (0.51) | MAPK1HPGDTSHRGSK3BF10 | |
| SCHEMBL12348258 | 0.86 | MAPK1 (0.51) | MAPK1HPGDTSHRGSK3BF10 | |
| SCHEMBL498073 | 0.86 | MAPK1 (0.51) | MAPK1HPGDTSHRGSK3BF10 | |
| SCHEMBL469776 | 0.86 | MAPK1 (0.51) | MAPK1HPGDTSHRGSK3BF10 | |
| SCHEMBL78371 | 0.86 | MAPK1 (0.51) | MAPK1HPGDTSHRGSK3BF10 | |
| SCHEMBL28025618 | 0.86 | MAPK1 (0.51) | MAPK1HPGDTSHRGSK3BF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150299160-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2015-10-22 | — | — | US | claimed |
| EP-2838897-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | Ranbaxy Laboratories Limited (IN) | 2015-02-25 | — | — | EP | claimed |
| WO-2013156936-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2013-10-24 | — | — | WO | claimed |
| US-20250066340-A1 | METHOD FOR SYNTHESIZING RIVAROXABAN | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2025-02-27 | — | — | US | disclosed |
| EP-4434983-A1 | METHOD FOR SYNTHESIZING RIVAROXABAN | Zhejiang Huahai Pharmaceutical Co., Ltd. (CN) | 2024-09-25 | — | — | EP | disclosed |
| CN-118176191-A | Synthesis method of rivaroxaban | 浙江华海药业股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| WO-2023088229-A1 | METHOD FOR SYNTHESIZING RIVAROXABAN | 浙江华海药业股份有限公司 | 2023-05-25 | — | — | WO | disclosed |
| WO-2023088229-A1 | METHOD FOR SYNTHESIZING RIVAROXABAN | 浙江华海药业股份有限公司 | 2023-05-25 | — | — | WO | disclosed |
| WO-2017076844-A1 | METHOD FOR PREPARATION OF THIOPHENE-2-CARBONYL CHLORIDES WITH OXALYL CHLORIDE | LONZA LTD (CH) | 2017-05-11 | — | — | WO | disclosed |
| WO-2017005606-A1 | METHOD FOR PREPARATION OF CARBOXYLIC ACID CHLORIDES FROM METHYL KETONES WITH TWO REAGENTS | LONZA LTD (CH) | 2017-01-12 | — | — | WO | disclosed |
| WO-2016202757-A1 | METHOD FOR PREPARATION OF CARBOXYLIC ACID CHLORIDES FROM METHYL KETONES | LONZA LTD (CH) | 2016-12-22 | — | — | WO | disclosed |
| US-20150133657-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN | RANBAXY LABORATORIES LIMITED (IN) | 2015-05-14 | — | — | US | disclosed |
| US-20150133657-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN | RANBAXY LABORATORIES LIMITED (IN) | 2015-05-14 | — | — | US | disclosed |
| EP-2855465-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN | Ranbaxy Laboratories Limited (IN) | 2015-04-08 | — | — | EP | disclosed |
| EP-2838897-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | Ranbaxy Laboratories Limited (IN) | 2015-02-25 | — | — | EP | disclosed |
| WO-2015011617-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN | RANBAXY LABORATORIES LIMITED (IN) | 2015-01-29 | — | — | WO | disclosed |
| WO-2013175431-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN | RANBAXY LABORATORIES LIMITED (IN) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013156936-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2013-10-24 | — | — | WO | disclosed |
| WO-2013046211-A1 | PROCESSES FOR THE PREPARATION OF 5-CHLORO-N-({(5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL) PHENYL]-1,3-OXAZOLIDIN-5-YL}METHYL)-2-THIOPHENE-CARBOXAMIDE AND INTERMEDIATES THEREOF | SYMED LABS LIMITED (IN) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013046211-A1 | PROCESSES FOR THE PREPARATION OF 5-CHLORO-N-({(5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL) PHENYL]-1,3-OXAZOLIDIN-5-YL}METHYL)-2-THIOPHENE-CARBOXAMIDE AND INTERMEDIATES THEREOF | SYMED LABS LIMITED (IN) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066340-A1 | METHOD FOR SYNTHESIZING RIVAROXABAN | F2, VKORC1, F12 | MAPK1 2089/4885HPGD 337/4885TSHR 857/4885 |
| US-20150299160-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | VKORC1, CYP3A4, TFPI | MAPK1 2718/4885HPGD 144/4885TSHR 2502/4885 |
| US-20150133657-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN | F2, VKORC1, F5 | MAPK1 3846/4885HPGD 449/4885TSHR 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.